United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Polaris Capital Management LLC

Polaris Capital Management LLC trimmed its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 7.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 131,850 shares of the biotechnology company’s stock after selling 10,100 shares during the period. United Therapeutics makes up about 2.2% of Polaris Capital Management LLC’s holdings, making the stock its 9th largest holding. Polaris Capital Management LLC’s holdings in United Therapeutics were worth $46,522,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Newbridge Financial Services Group Inc. purchased a new stake in shares of United Therapeutics during the fourth quarter worth about $25,000. Brooklyn Investment Group purchased a new stake in United Therapeutics during the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP acquired a new stake in United Therapeutics in the third quarter valued at $82,000. MassMutual Private Wealth & Trust FSB grew its position in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 58 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new stake in United Therapeutics during the third quarter worth about $90,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on UTHR shares. TD Cowen upped their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. The Goldman Sachs Group raised their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH lifted their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Argus upped their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $382.08.

Insider Activity

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. This trade represents a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $960,576.75. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 111,864 shares of company stock worth $41,036,365. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Trading Down 0.6 %

Shares of UTHR stock opened at $345.64 on Tuesday. The firm’s fifty day simple moving average is $362.37 and its 200 day simple moving average is $358.13. United Therapeutics Co. has a 1 year low of $210.64 and a 1 year high of $417.82. The firm has a market capitalization of $15.43 billion, a P/E ratio of 15.18, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.